Premium
An In Situ Depot for Continuous Evolution of Gaseous H 2 Mediated by a Magnesium Passivation/Activation Cycle for Treating Osteoarthritis
Author(s) -
Wan WeiLin,
Lin YuJung,
Shih PoChien,
Bow YuRu,
Cui Qinghua,
Chang Yen,
Chia WeiTso,
Sung HsingWen
Publication year - 2018
Publication title -
angewandte chemie
Language(s) - English
Resource type - Journals
eISSN - 1521-3757
pISSN - 0044-8249
DOI - 10.1002/ange.201806159
Subject(s) - depot , passivation , plga , osteoarthritis , chemistry , bioavailability , in situ , magnesium , glycolic acid , inflammation , nuclear chemistry , pharmacology , lactic acid , biochemistry , medicine , organic chemistry , in vitro , pathology , biology , bacteria , genetics , alternative medicine , archaeology , layer (electronics) , history
Inflammation is involved in many human pathologies, including osteoarthritis (OA). Hydrogen (H 2 ) is known to have anti‐inflammatory effects; however, the bioavailability of directly administered H 2 gas is typically poor. Herein, a local delivery system that can provide a high therapeutic concentration of gaseous H 2 at inflamed tissues is proposed. The delivery system comprises poly(lactic‐co‐glycolic acid) microparticles that contain magnesium powder (Mg@PLGA MPs). Mg@PLGA MPs that are intra‐muscularly injected close to the OA knee in a mouse model can act as an in situ depot that can evolve gaseous H 2 continuously, mediated by the cycle of passivation/activation of Mg in body fluids, at a concentration that exceeds its therapeutic threshold. The analytical data that are obtained in the biochemical and histological studies indicate that the proposed Mg@PLGA MPs can effectively mitigate tissue inflammation and prevent cartilage from destruction, arresting the progression of OA changes.